SCHEMBL1801441 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	CYP11B2	P19099	10/20	0.52

▸	CYP11B1	P15538	9/20	0.52

▸	SLC2A1	P11166	1/20	0.51

▸	CCNC	P24863	1/20	0.47

▸	CDK8	P49336	1/20	0.47

▸	CYP17A1	P05093	4/20	0.45

▸	CYP19A1	P11511	2/20	0.45

▸	PPARG	P37231	1/20	0.45

▸	PPARD	Q03181	1/20	0.45

▸	PPARA	Q07869	1/20	0.45

▸	POLB	P06746	1/20	0.45

▸	CYP2C9	P11712	1/20	0.45

▸	CYP3A4	P08684	1/20	0.45

▸	FFAR1	O14842	1/20	0.44

▸	KDM4E	B2RXH2	1/20	0.43

▸	ALDH1A1	P00352	1/20	0.43

▸	HPGD	P15428	1/20	0.43

▸	HSD17B10	Q99714	1/20	0.43

▸	MTNR1A	P48039	1/20	0.43

▸	MTNR1B	P49286	1/20	0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL19209442	0.93	SLC2A1 (0.53)	CYP11B2CYP11B1SLC2A1CCNCCDK8
SCHEMBL1803698	0.89	CYP11B2 (0.48)	CYP11B2CYP11B1CCNCCDK8CYP17A1
SCHEMBL1889329	0.89	CYP11B2 (0.49)	CYP11B2CYP11B1SLC2A1CCNCCDK8
SCHEMBL1805030	0.88	CYP11B2 (0.47)	CYP11B2CYP11B1CCNCCDK8CYP17A1
SCHEMBL16605161	0.87	SLC2A1 (0.49)	SLC2A1CCNCCDK8CYP17A1PPARG
SCHEMBL15948978	0.87	CYP11B2 (0.47)	CYP11B2CYP11B1CCNCCDK8CYP17A1
SCHEMBL1804925	0.86	CYP11B2 (0.45)	CYP11B2CYP11B1CCNCCDK8CYP17A1
SCHEMBL19209478	0.86	XDH (0.48)	CYP11B2CYP11B1CCNCCDK8CYP17A1
SCHEMBL1889009	0.86	FFAR1 (0.54)	POLBFFAR1MTNR1AMTNR1B
SCHEMBL12660792	0.85	POLB (0.52)	POLBFFAR1KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
WO-2026099533-A1	TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) WITH GPBP1 INHIBITORS	UNIVERSITAT DE VALÈNCIA (ES)	2026-05-15	—	—	WO	claimed
US-20160184274-A1	Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition	UNIVERSITAT DE VALENCIA (ES)	2016-06-30	—	—	US	claimed
US-9199936-B2	GPBP inhibition using Q2 peptidomimetics	Fibrostatin Sociedad Limitada (ES)	2015-12-01	—	—	US	claimed
EP-2496544-B1	GPBP INHIBITION USING Q2 PEPTIDOMIMETICS	FIBROSTATIN S L (SE)	2014-08-20	—	—	EP	claimed
US-20140080852-A1	GPBP inhibition using Q2 peptidomimetics	FIBROSTATIN, S.L. (ES)	2014-03-20	—	—	US	claimed
US-20110105545-A1	GPBP inhibition using Q2 peptidomimetics	FIBROSTATIN, S.L. (ES)	2011-05-05	—	—	US	claimed
WO-2026099533-A1	TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) WITH GPBP1 INHIBITORS	UNIVERSITAT DE VALÈNCIA (ES)	2026-05-15	—	—	WO	disclosed
US-10544083-B2	GPBP inhibition using Q2 peptidomimetics	UNIVERSITAT DE VALÈNCIA (ES)	2020-01-28	—	—	US	disclosed
US-10544083-B2	GPBP inhibition using Q2 peptidomimetics	UNIVERSITAT DE VALÈNCIA (ES)	2020-01-28	—	—	US	disclosed
EP-3049815-B1	GOODPASTURE ANTIGEN BINDING PROTEIN DETECTION AND INHIBITION AND ITS USE IN DIABETES	FIBROSTATIN SL (ES)	2019-03-13	—	—	EP	disclosed
US-20180179139-A1	GPBP inhibition using Q2 peptidomimetics	FIBROSTATIN, S.L. (ES)	2018-06-28	—	—	US	disclosed
US-20180179139-A1	GPBP inhibition using Q2 peptidomimetics	FIBROSTATIN, S.L. (ES)	2018-06-28	—	—	US	disclosed
US-20170204197-A1	Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes	FIBROSTATIN S L (ES)	2017-07-20	—	—	US	disclosed
US-8586776-B2	GPBP inhibition using Q2 peptidomimetics	FIBROSTATIN, S.L. (ES)	2013-11-19	—	—	US	disclosed
EP-2496544-A1	GPBP INHIBITION USING Q2 PEPTIDOMIMETICS	Fibrostatin, S.L. (SE)	2012-09-12	—	—	EP	disclosed
WO-2011054530-A1	GPBP INHIBITION USING Q2 PEPTIDOMIMETICS	FIBROSTATIN, S.L. (ES)	2011-05-12	—	—	WO	disclosed
WO-2011054530-A1	GPBP INHIBITION USING Q2 PEPTIDOMIMETICS	FIBROSTATIN, S.L. (ES)	2011-05-12	—	—	WO	disclosed
US-20110105545-A1	GPBP inhibition using Q2 peptidomimetics	FIBROSTATIN, S.L. (ES)	2011-05-05	—	—	US	disclosed
US-20110105545-A1	GPBP inhibition using Q2 peptidomimetics	FIBROSTATIN, S.L. (ES)	2011-05-05	—	—	US	disclosed
US-20110105545-A1	GPBP inhibition using Q2 peptidomimetics	FIBROSTATIN, S.L. (ES)	2011-05-05	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20170204197-A1	Goodpasture Antigen Binding Protein Detection and Inhibition and its Use in Diabetes	CD2BP2, SAP30BP, LY96	CYP11B2 4222/4885CYP11B1 4753/4885SLC2A1 201/4885
US-10544083-B2	GPBP inhibition using Q2 peptidomimetics	HSP90B1, ERP44, HSPA5	CYP11B2 2503/4885CYP11B1 2299/4885SLC2A1 2375/4885
US-20140080852-A1	GPBP inhibition using Q2 peptidomimetics	HSP90B1, ERP44, HSPA5	CYP11B2 2503/4885CYP11B1 2299/4885SLC2A1 2375/4885
US-20110105545-A1	GPBP inhibition using Q2 peptidomimetics	HSP90B1, ERP44, HSPA5	CYP11B2 2503/4885CYP11B1 2299/4885SLC2A1 2375/4885
US-20160184274-A1	Methods for inhibiting mesenchymal phenotype after epithelial-to-mesenchymal transition	VIM, EPCAM, CDH1	CYP11B2 4800/4885CYP11B1 4835/4885SLC2A1 2740/4885
US-20180179139-A1	GPBP inhibition using Q2 peptidomimetics	HSP90B1, ERP44, HSPA5	CYP11B2 2503/4885CYP11B1 2299/4885SLC2A1 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.